SOPHiA GENETICS announced that Unilabs is live on the SOPHiA DDM Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD- status in solid tumors and provide expedited analysis across its network in Switzerland. The implementation of SOPHiAGENETICS' technology across Switzerland will support the company's ability to offer leading testing and analysis to its customer-base and help further the use of precision medicine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.69 USD | -2.70% | -6.20% | -0.42% |
05-07 | Transcript : SOPHiA GENETICS SA, Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | SOPHiA GENETICS SA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.42% | 306M | |
+10.29% | 3,082B | |
+8.12% | 84.92B | |
+5.55% | 78.23B | |
-13.73% | 54.06B | |
+19.98% | 45.87B | |
-24.43% | 46.79B | |
+21.26% | 42.65B | |
+60.27% | 37.28B | |
-9.36% | 24.89B |
- Stock Market
- Equities
- SOPH Stock
- News SOPHiA GENETICS SA
- SOPHiA GENETICS Announces Unilabs Using Its AI Technology to Detect Homologous Recombination Deficiency